Presented by Biovays…

• The battle for Biogen was all over the news today as Carl Icahn claimed victory over 2 of 4 board seats. [Xconomy], [Bloomberg]

• Not only did Elan and BMS talks break down, but they hardly ever happened – talk about hype! [The Street]

• Merck wants to sell its animal health business – valuation around $5 billion say sources. [WSJ]

• Doctor asks FDA to stop reviewing Lilly’s new anti-clotting drug Prasugrel, says risk of major bleeding and cancer. Yikes!!! [FierceBiotech]

• Almirall gets FDA approval for migraine drug. [Reuters]

• The FDA gives a thumbs down to Advanced Life Science’s Restanza (cethromycin), cites lack of efficacy. [RedOrbit]

• GSK is looking for start-ups! [The Deal]

• Finally, Mylan and Endo Pharmaceuticals faced a grilling on Capitol Hill today over legislation to prevent pharmaceutical patent settlements that delay the introduction of generic drugs. [WSJ]

Anonymous Tip? Laid off? Contact us: hr AT iguanabio DOT com

Related Posts